Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Enzo Life Sciences’ high-sensitivity Grp78/BiP ELISA kit is an endoplasmic reticulum-specific homologue of Hsp70, serving as a critical stress-sensing chaperone and regulator of the unfolded protein response (UPR). Grp78 helps fold misfolded proteins, prevent protein aggregation, and regulate protein degradation, synthesis, transportation, and oligomerization.
March 2014—Helix Elite is the first molecular product line from Microbiologics. It includes 13 molecular standards—intended to facilitate the development, validation, and monitoring of molecular assays—for microorganisms that are difficult to grow or cannot be cultured, such as Cryptosporidium and norovirus.
March 2014—Qiagen last year enrolled molecular diagnostics laboratories in an early access program to complete the development of a Web-based solution to deliver faster, easier-to-use, and high-confidence clinical interpretation and reporting of observed gene variants in data from NGS-based tests.
March 2014—Clarient Diagnostic Services, a GE Healthcare company, has modified its facility in Houston to support a full range of clinical diagnostic testing for cancer. The facility, which operates under the name SeqWright Genomic Services, is a CLIA-certified lab offering nucleic acid sequencing and genomics services.
Definiens received the 2013 Global Frost & Sullivan Award for Company of the Year for Global Tissue Diagnostics and Pathology Imaging Solutions.
March 2014—Audit MicroControls added the Linearity FD D-Dimer PathFast Immunoanalyzer, five levels, to its line of calibration verification/linearity products. It is intended to simulate human patient serum samples for the purpose of determining linearity, calibration verification, and verification of reportable range for D-dimer.
March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.
March 2014—Bio SB launched the Normal Human Tissue Micro Array and the Infectious Disease Cell Line Micro Array. The NH-TMA arrays are available in 11- or 23-core configurations, allowing testing of multiple tissues on one slide, and are validated for use with more than 100 antibodies in immunohistochemistry.
March 2014—Promega launched the QuantiFluor One dsDNA System, a sensitive, dsDNA-specific fluorescent dye for use in research and clinical workflows. The dye system is integrated into the Promega Quantus Fluorometer and GloMax detection instruments but is compatible with any fluorometer capable of measuring the appropriate fluorescence excitation and emission spectra.
March 2014—The Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, New York City, have adopted Qiagen’s Ingenuity Variant Analysis solution for research and translational genomics applications related to characterizing and identifying rare diseases.
